Physician profile
Joseph Walsh
NPI 1255309340
$2,050.94
in general payments reported to CMS, 2019-2025
13 companies · $352 in 2025
The $352 reported for 2025 was more than what 86% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $181 · 2021: $354 · 2022: $399 · 2023: $255 · 2024: $200 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $516.02 | 2021-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $382.49 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $249.96 | 2022-2023 | Nuzyra |
| Tetraphase Pharmaceuticals, INC. | $177.79 | 2019-2020 | |
| Boston Scientific Corporation | $141.34 | 2020 | |
| Avanir Pharmaceuticals, INC. | $124.92 | 2021 | |
| Astellas Pharma US INC | $124.83 | 2024 | Veozah |
| United Therapeutics Corporation | $124.56 | 2021 | |
| Cipher Pharmaceuticals US LLC | $106.84 | 2025 | Spinosad, Natroba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.37 | 2023 | Rexulti, Nuedexta |
| Xeris Pharmaceuticals, INC. | $21.38 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.